Using bacteria and worms in the battle against Alzheimer’s disease
National Hellenic Research Foundation
Alzheimer’s disease (AD) is the most common form of dementia, a condition with a tremendous socioeconomic impact that remains incurable. The aim of this project is the discovery of therapeutic compounds against AD. By taking advantage of methods of molecular evolution, the team will attempt to identify compounds that inhibit the neurotoxicity caused by the formation of oligomers/aggregates of the amyloid β (Αβ) peptide. For this, an innovative approach will be implemented, where large libraries of small molecules will be biosynthesized rapidly in genetically modified Escherichia coli cells and then screened for bioactivity by feeding them directly to transgenic strains of Caenorhabditis elegans that serve as models of human AD. The compounds that will be identified to inhibit or reverse the AD phenotype will be subsequently examined for their ability to prevent cytotoxicity due to Αβ oligomerization/aggregation in human neurons. The identified bioactive molecules will become potential therapeutic compounds against AD.
Final Report (in Greek)
Niki Chondrogianni, Research Associate, National Hellenic Research Foundation
Georgios Skretas, Research Assistant, National Hellenic Research Foundation